Satoko Ito, MD, PhD
Postdoctoral FellowAbout
Research
Publications
2025
Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis
Glaeser-Khan S, Ito S, Sra M, Richmond R, Bona R, Krumholz H, Croteau S, Cuker A, Goshua G. Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis. Blood Advances 2025, 9: 6237-6245. PMID: 40795232, PMCID: PMC12744270, DOI: 10.1182/bloodadvances.2025016822.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioSevere hemophilia AIntracranial hemorrhageEmicizumab prophylaxisHemophilia ASevere HAWTP thresholdStandard careProphylactic factor replacementUS societal perspectiveInfants Aged 0Markov cohort modelLifetime time horizonCost-effectiveness ratioProbabilistic sensitivity analysesFVIII inhibitorsBleeding riskFactor replacementSevere complicationsEmicizumabAccess placementCentral venous access placementPrimary outcomeProphylaxisNeurological disabilityUnderstanding Risk-Deleted Disability-Adjusted Life-Years What’s Left Behind
Goshua G, Wang D, Ito S, Ng D, Pandya A. Understanding Risk-Deleted Disability-Adjusted Life-Years What’s Left Behind. Journal Of The American College Of Cardiology 2025, 86: 2130-2132. PMID: 41298026, DOI: 10.1016/j.jacc.2025.09.1574.Peer-Reviewed Original ResearchEarly discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy
Hunter C, Chetlapalli K, Ito S, Bewersdorf J, Boddu P, Browning S, Halene S, Parker T, Huntington S, Kothari S, Mendez L, Neparidze N, Sethi T, Stahl M, Podoltsev N, Zeidan A, Shallis R, Goshua G. Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy. Blood 2025, 146: 6208. DOI: 10.1182/blood-2025-6208.Peer-Reviewed Original ResearchEarly discharge programAbsolute neutrophil countLow absolute neutrophil countAcute myeloid leukemiaNext therapyIntensive chemotherapyTraditional cohortDirect costsHospital dischargeMyeloid leukemiaDirect costs of careOutpatient clinical careLonger hospitalInpatient bed usePatient's absolute neutrophil countDays of antimicrobial therapyCohort of consecutive patientsCost of careRed blood cell transfusionProgram cost savingsAssociated with longer hospitalSecond-line therapyBlood cell transfusionKaplan-Meier methodRisk exposure periodCost savings across bone marrow testing strategies in persons with suspected monoclonal gammopathy of undetermined significance
Sra M, Chetlapalli K, Ito S, Ng D, Patel K, Liu Y, Goshua G. Cost savings across bone marrow testing strategies in persons with suspected monoclonal gammopathy of undetermined significance. Blood 2025, 146: 4409-4409. DOI: 10.1182/blood-2025-4409.Peer-Reviewed Original ResearchHigh-risk SMMIncremental net monetary benefitMayo Clinic modelCare of individualsBone marrow biopsyMultiple myelomaRisk prediction modelDeterministic sensitivity analysisCost-effective strategyDisease progressionDaratumumab monotherapyLifetime cost-effectivenessSMM patientsMarrow biopsyMonoclonal gammopathyBlood testsClinical modelBaseline prevalenceMayo Clinic Risk StratificationUS health system perspectiveCare of peopleProgression free survivalOverall survival benefitWillingness-to-pay thresholdsBone marrow testsRaising the bar in maternofetal hematology: Cost-effectiveness of iron deficiency screening in pregnancy across ferritin-based thresholds
Wang D, Sra M, Ito S, Cuker A, Goshua G. Raising the bar in maternofetal hematology: Cost-effectiveness of iron deficiency screening in pregnancy across ferritin-based thresholds. Blood 2025, 146: 598. DOI: 10.1182/blood-2025-598.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioFerritin thresholdIron deficiencyNo screeningAdverse maternal-fetal outcomesUS health system perspectiveProspective dataTreatment of iron deficiencyUniversal screeningCost-effectiveness analysisMaternal-fetal outcomesIntravenous iron dextranIntravenous iron supplementationIron deficiency screeningTrimester of pregnancyIron deficiency anemiaCost-effective strategyTreatment of IDCost-effectiveness ratioPrevalence of IDSocietal perspectiveAmerican SocietyDeterministic sensitivity analysisProbabilistic sensitivity analysesInternal model validationCost-effectiveness of heparin-induced thrombocytopenia (HIT) diagnostic strategies: Rapid PF4/heparin versus ELISA-based antibody testing strategies in the care of hospitalized people with suspected HIT
Allen C, Ito S, Cuker A, Goshua G. Cost-effectiveness of heparin-induced thrombocytopenia (HIT) diagnostic strategies: Rapid PF4/heparin versus ELISA-based antibody testing strategies in the care of hospitalized people with suspected HIT. Blood 2025, 146: 1072. DOI: 10.1182/blood-2025-1072.Peer-Reviewed Original ResearchLatex immunoturbidimetric assaySerotonin release assayHeparin-Induced ThrombocytopeniaNon-heparin anticoagulantsELISA-based testAbstract Introduction PatientsMarkov simulation modelChemiluminescence immunoassayRapid testConfirmatory serotonin release assayHeparin-induced thrombocytopenia assaysUS health system perspectiveIntroduction PatientsCoagulation analyzerDiagnostic strategiesHeparin-induced thrombocytopenia patientsHeparin-induced thrombocytopenia testsHigh riskHigh risk of thrombosisAntibody testing strategiesBase-caseCohort of patientsIncremental cost-effectiveness ratioRisk of thrombosisTurnaround timeprimary prophylaxis with direct oral anticoagulants (DOACs) for transwomen taking estrogen is not cost-effective
Lopez J, Peterson S, Ito S, Wright L, Anawalt B, Garcia D, Goshua G. primary prophylaxis with direct oral anticoagulants (DOACs) for transwomen taking estrogen is not cost-effective. Blood 2025, 146: 6161. DOI: 10.1182/blood-2025-6161.Peer-Reviewed Original ResearchDirect oral anticoagulantsIncremental cost-effectiveness ratioChronic thromboembolic pulmonary hypertensionStandard of careQuality-adjusted life yearsPost-thrombotic syndromeDeep venous thrombosisVenous thromboembolismKaiser Permanente health planRelative risk reductionIntracranial hemorrhageOral anticoagulantsPulmonary embolismLow-dose direct oral anticoagulantsPersonal history of venous thromboembolismHistory of venous thromboembolismGeneral populationVenous thromboembolism risk reductionAMPLIFY-EXT trialBaseline bleeding riskThromboembolic pulmonary hypertensionUS societal perspectiveExogenous estrogen exposureAverage follow-upVenous thromboembolism riskCost-effectiveness of ribociclib plus endocrine therapy in HR-positive, HER2-negative early breast cancer in the United States.
Potnis K, Ito S, Kunst N, Richman I, Winer E, Goshua G. Cost-effectiveness of ribociclib plus endocrine therapy in HR-positive, HER2-negative early breast cancer in the United States. Journal Of Clinical Oncology 2025, 43: 11049-11049. DOI: 10.1200/jco.2025.43.16_suppl.11049.Peer-Reviewed Original ResearchHER2- early breast cancerEarly breast cancerIncremental cost-effectiveness ratioEndocrine therapyBreast cancerQuality-adjusted life yearsDeterministic sensitivity analysisHR-positiveHER2-negative early breast cancerWTP thresholdCost-effectiveness of ribociclibInvasive disease-free survivalDisease-free survival curvesAcceptable WTP thresholdDisease-free survivalBase-caseHigher WTP thresholdNonsteroidal aromatase inhibitorBase-case analysisCyclin-dependent kinase 4Cost-effectiveness ratioHER2-negativeCDK4/6 inhibitorsAromatase inhibitorsHealth system perspectiveAnchoring the Hemophilia Joint Health Score for Conventional Value Assessment in the Care of People Living with Severe Hemophilia A
Ito S, Sra M, Goshua G. Anchoring the Hemophilia Joint Health Score for Conventional Value Assessment in the Care of People Living with Severe Hemophilia A. PharmacoEconomics 2025, 43: 761-764. PMID: 40410545, PMCID: PMC12167127, DOI: 10.1007/s40273-025-01508-w.Peer-Reviewed Original ResearchCost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening
Ito S, Xicola R, Sra M, Potnis K, Singh V, Gershkovich P, Stites E, Gibson J, Krumholz H, Llor X, Goshua G. Cost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening. Clinical Gastroenterology And Hepatology 2025, 23: 2328-2338.e9. PMID: 40315972, PMCID: PMC12354148, DOI: 10.1016/j.cgh.2025.03.006.Peer-Reviewed Original ResearchLynch syndromeIncremental cost-effectiveness ratioGermline testingColorectal cancerProspective Lynch Syndrome DatabaseColorectal cancer probandsNational Cancer Institute's SurveillancePre-/post-interventionPreventing cancer incidenceLynch syndrome screeningEnd Results ProgramCost-effective interventionHealth system perspectiveCost-effectiveCancer incidenceQuality-adjusted life expectancyInstitute's SurveillanceResults ProgramProspective interventionStandard-of-careCost-effectiveness ratioLS testingCohort studyGenetic testingPrimary outcome
News
News
- December 05, 2024
Drug Offers Cost-Effective Protection for Newborns with Genetic Bleeding Disorder
- December 06, 2023
New Research Sheds Light on Equitable Treatment Options for Pediatric Patients With Sickle Cell Disease
- May 30, 2023
Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease
Get In Touch
Contacts
Email